Status:
COMPLETED
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
Lead Sponsor:
Sun Yat-sen University
Conditions:
IgA Nephropathy
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
Detailed Description
It has been reported that hyperuricemia is a risk factor for progression of IgAN. This will be a prospective, randomized study. Eligible IgAN patients will be randomized into the treatment group and t...
Eligibility Criteria
Inclusion
- Subjects of either sex, more than 18 years old, the range of age is 18 to 70 year old.
- Biopsy-proven IgA nephropathy.
- Proteinuria between 0.15g/d and 3.0g/d; and serum albumin level\>3.5g/dl.
- Serum creatinine \< 3 mg/dl.
- Uric acid \> 6 mg//dl (360umol/dl) in female; Uric acid \>7mg/dl (420umol/dl ) in male.
- No history of taking ACEI or ARB within 2 weeks.
- Blood pressure \< 180/110 mmHg.
- Subjects who agree to participate in the study and sign the informed consent.
Exclusion
- Patients who have received prednisone or immunosuppressive drugs within 2 months.
- Patients who must take ACEI or ARB due to other diseases.
- Patients who have the history of allergy to allopurinol.
- Unwillingness to follow the study protocol.
- Active gout within 4 weeks.
- Pregnancy or unwillingness to use contraception.
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00793585
Start Date
July 1 2007
End Date
June 1 2009
Last Update
May 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The 1st Affiliated Hospital, Sun Yet-sen University
Guangzhou, Guangdong, China, 510080